The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | The role of belantamab mafodotin in multiple myeloma: the DREAMM-7 and DREAMM-8 trials
Fredrik Hellem Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the role of the antibody-drug conjugate (ADC) belantamab mafodotin in treating multiple myeloma. Positive results from the DREAMM-7 trial (NCT04246047) show the efficacy of belantamab mafodotin with bortezomib and dexamethasone, and results from the DREAMM-8 trial (NCT04484623) with pomalidomide and dexamethasone are awaited. Dr Schjesvold predicts that belantamab mafodotin will become a standard second-line treatment for multiple myeloma within the next year. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria for lectures and educational material: Skylite DX, Schain, Novartis, Janssen-Cilag, Takeda, Pfizer, Oncopeptides, Amgen, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Celgene, GlaxoSmithKline, Abbvie
Consultancy: Janssen-Cilag, Takeda, Oncopeptides, Sanofi, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Abbvie
Research Funding: Janssen-Cilag, Oncopeptides, Sanofi, Targovax, Celgene, GlaxoSmithKline
